A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of Breast cancer from North India

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Siddiqui, Sarah ^a   Chattopadhyay, Shilpi ^a   Akhtar, Md Salman ^a   Najm, Mohammad Zeeshan ^a   Deo, S V S ^b   Shukla, N K ^b   Husain, Syed Akhtar ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; GENOMIC DNA;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; FEMALE; FGFR2 GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INDIA; INDIAN; LIFESTYLE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST TUMOR; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; RISK; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84908180928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110426     Document Type: Article

References (88)

1. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
2. Hortobagyi GN, Garza SJ, Pritchard K, Amadori D., Haidinger R, et al. (2005) The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6: 391-401.
3. Anderson BO, Jakesz R (2008) Breast cancer issues in developing countries: an overview of the breast health global initiative. World J Surg 32: 2579-85.
4. Porter P (2008) Westernizing women's risks? Breast cancer in lower-income countries. N Engl J Med 358: 213-6.
5. Green M, Raina V (2008) Epidemiology, screening and diagnosis of breast cancer in the Asia-Pacific region: current perspectives and important considerations. Asia Pac J Clin Oncol 4: 5-13.
6. Agarwal G, Pradeep PV, Aggarwal V, Yip C.H., Cheung PS (2007) Spectrum of breast cancer in Asian women. World J Surg 31: 1031-40.
7. Leong SPL, Shen ZZ, Liu T.J., Agarwal G., Tajima T, et al. (2010) Is breast cancer the same disease in Asian and Western countries? World J Surg 34(10): 2308-24.
8. Takiar R, Srivastav A (2008) Time trend in breast and cervix cancer of women in India - (1990-2003). Asian Pac J Cancer Prev 9(4): 777-80.
9. Yeole BB (2008) Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Asian Pac J Cancer Prev 9(1): 119-22.
10. Nandakumar A, Ramnath T, Chaturvedi M (2010) The magnitude of cancer breast in India: a summary. Indian J Surg Oncol 1(1): 8-9.
11. Murthy NS, Agarwal UK, Chaudhry K, Saxena S (2007) A study on time trends in incidence of breast cancer - Indian scenario. Eur J Cancer Care 16: 185-6.
12. Breast cancer in developing countries (2009) Lancet 374(9701): 1567.
13. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360: 187-195.
14. Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40: 17-22.
15. Antoniou AC, Pharoah PD, McMullan G, Day N.E., Ponder BA, et al. (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21: 1-18.
16. Chen YC, Hunter DJ (2005) Molecular epidemiology of cancer. CA Cancer J Clin 55(1): 45-54. quiz7.
17. Easton DF, Pooley KA, Dunning A.M., Pharoah PD, Thompson D, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148): 1087-1093.
18. Hunter DJ, Kraft P, Jacobs K.B., Cox DG, Yeager M, et al. (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39(7): 870-874.
19. Ahmed S, Thomas G, Ghoussaini M., Healey CS, Humphreys MK, et al. (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41: 585-590.
20. Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9: 321-345.
21. Turnbull C, Ahmed S, Morrison J., Pernet D, Renwick A, et al. (2010) Genomewide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504-507.
22. Stacey SN, Manolescu A, Sulem P., Rafnar T, Gudmundsson J, et al. (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39: 865-869.
23. Ghoussaini M, Pharoah PD (2009) Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol 5: 689-701.
24. Ghoussaini M, Fletcher O, Michailidou K., Turnbull C, Schmidt MK, et al. (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44: 312-318.
25. Thomas G, Jacobs KB, Kraft P, Yeager M., Wacholder S, et al. (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41: 579-584.
26. Taylor JG, Choi EH, Foster C.B., Chanock SJ (2001) Using genetic variation to study human disease. Trends Mol Med 7(11): 507-12.
27. Pharoah PD, Antoniou A, Bobrow M., Zimmern RL, Easton DF, et al. (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31: 33-36.
28. Collins FS, Guyer MS, Charkravarti A (1997) Variations on a theme: cataloguing human DNA sequence variation. Science 278: 1580-1581.
29. Chakravarti A (1998) It's raining SNPs, hallelujah? Nat Genet 19: 216-217.
30. Mehrian-Shai R, Reichardt JK (2004) A renaissance of "biochemical genetics"? SNPs, haplotypes, function, and complex diseases. Mol Genet Metab 83: 47-50.
31. Wesche J, Haglund K, Haugsten EM (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437: 199-213.
32. Dillon C, Spencer-Dene B, Dickson C (2004) A crucial role for fibroblast growth factor signaling in embryonic mammary gland development. J Mammary Gland Biol Neoplasia 9: 207-215.
33. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
34. Katoh M (2008) Cancer genomics and genetics of FGFR2. Int J Oncol 33: 233-237.
35. Jang JH, Shin KH, Park JG (2001) Mutations in FGFR2 and FGFR3 genes associated with human gastric and colorectal cancers. Cancer Res 61: 3541-3543.
36. Pollock PM, Gartside MG, Dejeza L.C., Powell MA, Mallon MA, et al. (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26: 7158-7162.
37. Penault-Llorca F, Bertucci F, Ade'laïde J, Parc P, Coulier F, et al. (2000) Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2: 311-320.
38. Adnane J, Gaudray P, Dionne C.A., Crumley G., Jaye M, et al. (1991) BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6: 659-63.
39. Ingersoll RG, Paznekas WA, Tran A.K., Scott AF, Jiang G, et al. (2001) Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and variations. Cytogenet Cell Genet 94: 121-126.
40. Huijts PEA, Vreeswijk MPG, Kroeze-Jansema KHG, Jacobi CE, Seynaeve C, et al. (2007) Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a dutch cohort of incident breast cancer cases. Breast Cancer Res 9: R78.
41. Raskin L, Pinchev M, Arad C., Lejbkowicz F, Tamir A, et al. (2008) FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev 17: 1060-1065.
42. Hemminki K, Müller-Myhsok B, Lichtner P, Engel C, Chen B, et al. (2010) Low-risk variants FGFR2, TNRC9 and LSP1 in german familial breast cancer patients. Int J Cancer 126: 2858-2862.
43. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante S.J., Luo J., et al. (2010) FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in african-american and younger women. Carcinogenesis 31: 1417-1423.
44. Fu F, Wang C, Huang M., Song C, Lin S, et al. (2012) Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women. Tohoku J Exp Med 226: 221-229.
45. Jara L, Gonzalez-Hormazabal P, Cercen OK, Di Capua GA, Reyes JM, et al. (2013) Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population. Breast Cancer Res Treat 137: 559-569.
46. Liang J, Chen P, Hu Z., Zhou X, Chen L, et al. (2008) Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 29: 2341-2346.
47. Kawase T, Matsuo K, Suzuki T., Hiraki A, Watanabe M, et al. (2009) FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan. Int J Cancer 125: 1946-1952.
48. Long J, Zhang B, Signorello L.B., Cai Q., Halverson SD, et al. (2013) Evaluating Genome-Wide Association Study-Identified Breast Cancer Risk Variants in African-American Women. PLoS ONE 8(4): e58350.
49. Udler MS, Meyer KB, Pooley K.A., Karlins E., Struewing JP, et al. (2009) FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet 18(9): 1692-1703.
50. Zheng W, Cai Q, Signorello L.B., Long J., Hargreaves MK, et al. (2009) Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol Biomarkers Prev 18: 2761-2764.
51. Huo D, Zheng Y, Ogundiran T.O., Adebamowo C., Nathanson KL, et al. (2012) Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 33: 835-840.
52. Chen F, Lv M, Xue Y., Zhou J, Hu F, et al. (2012) Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. Immunogenetics 64: 71-76.
53. Rebbeck TR, DeMichele A, Tran T.V., Panossian S., Bunin GR, et al. (2009) Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis 30: 269-274.
54. Chen XH, Li ZQ, Chen Y, Feng YM (2011) Risk of aggressive breast cancer in women of Han nationality carrying TGFB1 rs1982073 C allele and FGFR2 rs1219648 G allele in North China. Breast Cancer Res Treat 125: 575-582.
55. Wang H, Yang Z, Zhang H (2013) Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk. Breast Cancer Res Treat 137: 511-522.
56. Meyer KB, Maia A, O'Reilly M, Teschendorff AE, Chin S, et al. (2008) Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 6: e108.
57. Boyarskikh UA, Zarubina NA, Biltueva1 JA, Sinkina TV, Voronina EN, et al. (2009) Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia. European Journal of Human Genetics 17: 1688-1691.
58. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
59. Barrett JC, Fry B, Maller J., Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
60. Samson M, Rama R, Swaminathan R., Sridevi V, Nancy KN, et al. (2009) CYP17 (T-34C), CYP19 (Trp39Arg), and FGFR2 (C-906T) Polymorphisms and the Risk of Breast Cancer in South Indian Women. Asian Pacific J Cancer Prev 10: 111-114.
61. Garcia-Closas M, Hall P, Nevanlinna H., Pooley K, Morrison J, et al. (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4(4): e1000054.
62. Luqmani YA, Graham M, Coombes RC (1992) Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 66: 273-80.
63. Tozlu S, Girault I, Vacher S., Vendrell J, Andrieu C, et al. (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a largescale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13: 1109-1120.
64. Zang XP, Pento JT (2002) Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 18: 573-580.
65. Key T. Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst 94: 606-616.
66. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285.
67. Clavel-Chapelon F, E3N-EPIC Group 1 (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86: 723-727.
68. Gao YT, Shu XO, Dai Q, Potter J.D., Brinton LA, et al. (2000) Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 87: 295-300.
69. Madigan MP, Zeigler RG, Benichou J, Byrne C., Hoover RN (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87: 1681-1685.
70. Tavani A, Gallus S, La Vecchia C, Negri E, Montella M, et al. (1999) Risk factors for breast cancer in women under 40 years. Eur J Cancer 35: 1361-7.
71. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2(3): 133-40.
72. Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6: 229-239.
73. Rao DN, Ganesh B, Desai PB (1994) Role of reproductive factors in breast cancer in a low-risk area: a case-control study. Br J Cancer 70: 129-32.
74. Gajalakshmi V, Mathew A, Brennan P., Rajan B, Kanimozhi V, et al. (2009) Breast feeding and breast cancer risk in India: a multicenter case-control study. Int J Cancer 125: 662-5.
75. Chan M, Ji SM, Liaw C.S., Yap YS, Law HY, et al. (2012) Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population. Breast Cancer Res Treat 136(1): 209-20.
76. Moffa AB, Tannheimer SL, Ethier SP (2004) Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2: 643.
77. Huijts PEA, Dongen MV, de Goeij MCM, Moolenbroek AJV, Blanken F, et al. (2011) Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Cancer Research 13: R72.
78. Carroll JS, Meyer CA, Song J, Li W., Geistlinger TR, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289-1297.
79. Haugsten EM, Wiedlocha A, Olsnes S., Wesche J (2010) Roles of Fibroblast Growth Factor Receptors in Carcinogenesis. Mol Cancer Res 8: 1439-1452.
80. Turner N, Lambros MB, Horlings H.M., Pearson A., Sharpe R, et al. (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013-23.
81. Cha JY, Lambert QT, Reuther G.W., Der CJ (2008) Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 6: 435-45.
82. Tannheimer SL, Rehemtulla A, Ethier SP (2000) Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000 2: 311-20.
83. Moffa AB, Ethier SP (2007) Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J Cell Physiol 210: 720-731.
84. Brooks N, Kilgour E, Smith PD (2012) Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer. Clin Cancer Res 18: 1855-1862.
85. Hynes NE, Dey JH (2010) Potential for Targeting the Fibroblast Growth Factor Receptors in Breast Cancer Cancer Res 70: 5199-5202.
86. Zhao WM, Wang L, Park H., Chhim S, Tanphanich M, et al. (2010) Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res 16: 5750-8.
87. Bai A, Meetze K, Vo N.Y., Kollipara S., Mazsa EK, et al. (2010) GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 70: 7630-9.
88. Koziczak M, Holbro T, Hynes NE (2004) Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23: 3501-8.